Patents by Inventor Kyung-Sook Chung
Kyung-Sook Chung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140228357Abstract: The present invention relates to novel compounds as HIF-1? inhibitors, manufacturing process thereof, and a pharmaceutical compositions. The compounds according to the present invention having inhibition activity against HIF-1?, can be used as a therapeutic prevention and/or treatment for various solid cancers such as colon cancer, liver cancer, stomach cancer and breast cancer. Also, the compounds according to the present invention are useful in the treatment of diabetic retinopathy and rheumatoid arthritis, which are aggravated by HIF-1?-mediated VEGFA expression.Type: ApplicationFiled: September 27, 2012Publication date: August 14, 2014Inventors: Kyeong Lee, Mi-Sun Won, Hwan-Mook Kim, Song-Kyu Park, Ki-Ho Lee, Chang-Woo Lee, Bo-Kyung Kim, Hyun-Seung Ban, Kyung-Sook Chung, Naik Ravi
-
Publication number: 20130237542Abstract: The present invention relates to a compound inhibiting HF-1 activity, a preparation method of the same, and a pharmaceutical composition comprising the same as an active ingredient. The compound of the present invention demonstrates anticancer activity not by non-selective cytotoxicity but by inhibiting the activity of HIF-1, the transcription factor playing an important role in cancer cell growth and metastasis. Accordingly, the compound or the pharmaceutically acceptable salt thereof according to the present invention inhibits HIF-1 activity, and therefore can be used as a therapeutic agent for solid tumors such as colon cancer, liver cancer, stomach cancer and breast cancer. In addition, the compound or the pharmaceutically acceptable salt thereof according to the present invention can be used as an active ingredient for a therapeutic agent for diabetic retinopathy or arthritis which may become worse when hypoxia-induced VEGF expression by HIF-1 increases.Type: ApplicationFiled: October 17, 2011Publication date: September 12, 2013Applicants: DONGGUK UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION, KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Kyeong Lee, Mi Sun Won, Hwan Mook Kim, Song Kyu Park, Kiho Lee, Ki Hoon Lee, Chang Woo Lee, Jung Joon Lee, Kyung Sook Chung, Bo Kyung Kim, Yinglan Jin, Seung-hee Lee
-
Patent number: 8486905Abstract: Provided are a composition for diagnosing cancer or screening an anticancer drug comprising an FLJ25416 gene or an antibody directed to a protein expressed from the FLJ25416 gene, a composition for treating cancer comprising an inhibitor of the gene or an inhibitor of the protein expressed from the gene and a pharmaceutically acceptable carrier, and a kit for diagnosing cancer comprising at least one of the FLJ25416 gene and the protein expressed from the FLJ25416 gene. The FLJ25416 gene is expressed at high level in specific cancer cells, and induces an increase in proliferation rate of normal cells. The expression of the gene is suppressed, which results in an inhibitory effect on cancer cell growth. Thus, the FLJ25416 gene can be used as a target gene for diagnosis or treatment of cancer.Type: GrantFiled: December 5, 2008Date of Patent: July 16, 2013Assignees: Korea Research Institute of Bioscience and Biotechnology, St. Pharm Co., Ltd.Inventors: Misun Won, Kyung-Sook Chung, Young-Joo Kim, Shin-Jung Choi, Young Il Yeom, Seon-Young Kim, Kyung Bin Song, Hee Gu Lee, Eun Young Song, Young Ho Kim, Ho Kyung Chun, Chae-Ok Yun, Moon Hee Kim, Kyeong-Eun Jung, Sun-Jung Cho
-
Publication number: 20130028957Abstract: The present invention provides a pharmaceutical composition for treating cancer, comprising at least one selected from deoxyribonucleic acids (DNA) for encoding small interfering RNA (siRNA) which complementarily binds to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, represented by sequence number 3, sequence number 5, and sequence number 7 to inhibit the intracellular expression of the FLJ25416 gene, antisense RNA which inhibits expression of the FLJ25416 gene, and short hairpin RNA (shRNA) which inhibits expression of the FLJ25416 gene. As the siRNA, which is complementary to the base sequence of the transcript (mRNA transcript) of the FLJ25416 gene, the antisense RNA, and the shRNA, according to the present invention, inhibit expression of the FLJ25416 gene which is known to be expressed in cancer cells, and thus kill cancer cells, the composition of the present invention can be used as a novel anti-cancer agent.Type: ApplicationFiled: November 1, 2010Publication date: January 31, 2013Inventors: Misun Won, Kyung-Sook Chung, Young Joo Kim, Hye Kyung Hong, Young Il Yeom, Chae Ok Yun, Yu-Kyoung Oh, Kyung Bin Song, Hee Gu Lee, Young Ho Kim, Moon Hee Kim, Kyeong-Eun Jung, Seok Hoon Song
-
Patent number: 8283129Abstract: Disclosed herein is a colorectal cancer marker for diagnosing colorectal cancer based on ESM-I overexpression in tissues, cells or body fluids of colorectal cancer patients. Disclosed also is the use of the colorectal cancer marker in the development of therapeutic agents for cancer and in the diagnosis and treatment of colorectal cancer.Type: GrantFiled: November 23, 2007Date of Patent: October 9, 2012Assignee: Korea Research Institute of Bioscience and BiotechnologyInventors: Eun Young Song, Mi Young Park, Hyang Sin Lee, Hee Gu Lee, Jae Wha Kim, In Seong Choe, Min A Kang, Mi Sun Won, Kyung-Sook Chung, Young Ho Kim, Ho Kyung Chun, Young Il Yeom, Seon-Young Kim
-
Publication number: 20120141488Abstract: Disclosed are novel GPCR (G Protein Coupled Receptor) proteins and genes encoding the same. Also provided is the use of the proteins and the genes. Particularly, contemplated are a novel GPCR (G Protein Coupled Receptor) polypeptide, a polynucleotide coding for the same, a recombinant vector carrying the polynucleotide or a fragment thereof, host cells transformed with the vector, a transgenic animal infected with the vector. Also, a composition for detecting a cancer marker, comprising an agent capable of measuring the expression level of mRNA or protein of the GPCR polynucleotide, a kit for the diagnosis of cancer, comprising the composition, and a method for detecting the GPCR polypeptide and a gene encoding the polypeptide are provided.Type: ApplicationFiled: September 7, 2009Publication date: June 7, 2012Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHInventors: Kyung Sook Chung, Mi Sun Won, Ji Won Ahn, Jeong Hae Choi, Hyang Sook Yoo, Young Il Yeom, Eun Young Song, Hae Gu Lee, Jae Hun Cheong, Chang Mo Kang
-
Publication number: 20110251097Abstract: The present invention relates to a composition for diagnosing colon cancer. The composition comprises at least one marker for measuring an mRNA or protein expression level of at least one gene specific for colon cancer. It can screen the genes which are overexpressed specifically only in colon cancer tissues or blood. The present invention can quantitatively analyze both the mRNA expression levels of the genes and the expression levels of the proteins encoded by the gene at the same time, thereby diagnosing colon caner of an early stage with a high level of reliability.Type: ApplicationFiled: April 20, 2009Publication date: October 13, 2011Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGYInventors: Eun Young Song, Hee Gu Lee, Young Il Yeom, Jae Wha Kim, Na Young Ji, Kyung-Sook Chung, Misun Won, Seon-Young Kim, Joo Heon Kim, Young Ho Kim, Ho Kyung Chun
-
Publication number: 20110201512Abstract: The present invention relates to a method for detecting a colon cancer in a human, comprising the steps of: (a) providing a biological sample from the human; and (b) detecting the level of a ATAD2 nucleic acid or a ATAD2 protein in the biological sample, relative to the level of the ATAD2 nucleic acid or the ATAD2 protein in a control sample from a normal human, wherein an increased level of the ATAD2 nucleic acid or the ATAD2 protein in the biological sample compared to the control sample indicates that the human has the colon cancer. The biomarker of this invention was identified using normal colon tissue, colon cancer tissue and metastatic cancer tissue derived from a colon cancer patient. Therefore, the accuracy and reliability of the present biomarker for colon cancer and/or metastasis are much more significantly improved. In addition, the biomarker of this invention permits to identify and predict colon cancer or metastasis in an accurate manner.Type: ApplicationFiled: June 24, 2010Publication date: August 18, 2011Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Hee Gu Lee, Eun Young Song, Young II Yeom, Jae Wha Kim, Jong Tae Kim, Kyung Sook Chung, Mi Sun Won, Hyun Hyo Suh, Joo Woong Park, Min Ah Kang
-
Publication number: 20110190163Abstract: A method comprising transforming Schizosaccharomyces pombe with a deletion cassette, constructed by four-round serial PCR, block PCR or total gene synthesis, containing a homologous recombination site is provided for preparing gene-targeted heterozygous deletion Schizosaccharomyces pombe. Also provided are gene-targeted hetero2ygous deletion Schizosaccharomyces pombe mutants prepared by the method, and a library of gene-targeted heterozygous deletion Schizosaccharomyces pombe mutants. Further, the library is useful in constructing a method and a kit for screening a drug's modes of action.Type: ApplicationFiled: August 27, 2008Publication date: August 4, 2011Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Kwang Lae Hoe, Dong Uk Kim, Mi Sun Won, Hyang Sook Yoo, Dong Sup Kim, Han Oh Park, Kyung Sook Chung, Young Joo Jang, Mi Young Nam, Sang Jo Han, Hin Jung Choi, Seung Tae Baek, Hyong Bai Kim, Kyung Sun Heo, Hye Mi Lee, Min Ho Lee, Jo Young Park
-
Publication number: 20110008370Abstract: Provided are a composition for diagnosing cancer or screening an anticancer drug comprising an FLJ25416 gene or an antibody directed to a protein expressed from the FLJ25416 gene, a composition for treating cancer comprising an inhibitor of the gene or an inhibitor of the protein expressed from the gene and a pharmaceutically acceptable carrier, and a kit for diagnosing cancer comprising at least one of the FLJ25416 gene and the protein expressed from the FLJ25416 gene. The FLJ25416 gene is expressed at high level in specific cancer cells, and induces an increase in proliferation rate of normal cells. The expression of the gene is suppressed, which results in an inhibitory effect on cancer cell growth. Thus, the FLJ25416 gene can be used as a target gene for diagnosis or treatment of cancer.Type: ApplicationFiled: December 5, 2008Publication date: January 13, 2011Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHInventors: Misun Won, Kyung-Sook Chung, Young-Joo Kim, Shin-Jung Choi, Young Il Yeom, Seon-Young Kim, Kyung Bin Song, Hee Gu Lee, Eun Young Song, Young Ho Kim, Ho Kyung Chun, Chae-Ok Yun, Moon Hee Kim, Kyeong-Eun Jung, Sun-Jung Cho
-
Publication number: 20100248244Abstract: Disclosed herein is a colorectal cancer marker for diagnosing colorectal cancer based on ESM-I overexpression in tissues, cells or body fluids of colorectal cancer patients. Disclosed also is the use of the colorectal cancer marker in the development of therapeutic agents for cancer and in the diagnosis and treatment of colorectal cancer.Type: ApplicationFiled: November 23, 2007Publication date: September 30, 2010Applicant: Korea Research Institute of Bioscience and BiotechnologyInventors: Eun Young Song, Mi Young Park, Hyang Sin Lee, Hee Gu Lee, Jae Wha Kim, In Seong Choe, Min A. Kang, Mi Sun Won, Kyung Sook Chung, Young Ho Kim, Ho Kyung Chun, Young Il Yeom, Seon-Young Kim
-
Publication number: 20100144708Abstract: The present invention relates to new heterocyclic compounds containing nitrogen atoms or pharmaceutically acceptable salts thereof, a process for the preparation thereof, and a pharmaceutical composition comprising the same for treatment of cancer. The compounds according to the present invention induce DNA damage due to reactive oxygen species to activate c-abl and p53, induce RhoB to generate apoptosis, and induce cell death by down-regulating Bcl2 involved in cell survival, which is generated by dysregulated signals via the mitochondria pathway, thereby inhibiting tumor cell growth and inducing apoptosis. Accordingly, the composition according to the present invention can be used to treat cancer.Type: ApplicationFiled: August 10, 2007Publication date: June 10, 2010Applicants: Korea Research Instititute of Bioscience and Biotechnology, Seoul Pharma, Co., Ltd.Inventors: Gyoon Hee Han, Eun Hyun Choi, Jee Sun Yang, Sung Hee Hong, Myung Sook Kim, Mi Sun Won, Kyung Sook Chung, Dong Myung Kim, Hyang Sook Yoo, Hwan Mook Kim, Song Kyu Park, Ki Ho Lee, Chang Woo Lee, Youn Woong Choi, Yong Mi Jeong, Byung Gu Min
-
Patent number: 6518484Abstract: The present invention provides a nucleic acid molecule isolated from the 5′ untranscribed region of a translationally controlled tumor protein (TCTP) gene from Arabidopsis. The nucleic acid molecule, referred to as TCTP promoter in the present invention, directs the high-level expression of a reporter gene that is properly placed under its control. The TCTP promoter initiates and regulates the gene expression to a level that is comparable to those by the currently available promoters in plant genetic engineering. A minimum of 300-bp region is enough for fill regulatory activity. The TCTP promoter is functional in all plant tissues tested with the highest activity in the meristem tissue of root tip. The present invention can be utilized to express useful genes to a high level in agronomically important plants.Type: GrantFiled: March 23, 2001Date of Patent: February 11, 2003Assignee: Korea Kumho Petrochemical Co., Ltd.Inventors: Jeong-Gu Kang, Ju Yun, Kyung-Sook Chung, Pill-Soon Song, Chung-Mo Park
-
Publication number: 20020108141Abstract: The present invention provides a nucleic acid molecule isolated from the 5′ untranscribed region of a translationally controlled tumor protein (TCTP) gene from Arabidopsis. The nucleic acid molecule, referred to as TCTP promoter in the present invention, directs the high-level expression of a reporter gene that is properly placed under its control. The TCTP promoter initiates and regulates the gene expression to a level that is comparable to those by the currently available promoters in plant genetic engineering. A minimum of 300-bp region is enough for fill regulatory activity. The TCTP promoter is functional in all plant tissues tested with the highest activity in the meristem tissue of root tip. The present invention can be utilized to express useful genes to a high level in agronomically important plants.Type: ApplicationFiled: March 23, 2001Publication date: August 8, 2002Inventors: Jeong-Gu Kang, Ju Yun, Kyung-Sook Chung, Pill-Soon Song, Chung-Mo Park